Tezampanel - Proniras

Drug Profile

Tezampanel - Proniras

Alternative Names: LY 293558; NGX 424

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Proniras Corporation; Raptor Pharmaceutical Corp
  • Class Analgesics; Antimigraines; Isoquinolines; Tetrazoles
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Seizures
  • Discontinued Migraine; Neuromuscular disorders; Thrombosis

Most Recent Events

  • 27 Apr 2018 Tezampanel licensed to Proniras worldwide
  • 27 Apr 2018 Preclinical trials in Seizures in USA (Parenteral) ,
  • 27 Apr 2018 Proniras intends to file an IND with the US FDA for Seizures (nerve agent induced) in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top